← Back to Search

Assisted Ventilation

VentFirst for Extremely Preterm Infants

N/A
Waitlist Available
Led By Karen Fairchild, MD
Research Sponsored by University of Virginia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 36 weeks' postmenstrual age
Awards & highlights
No Placebo-Only Group

Summary

This trial tests if giving extremely preterm babies breathing support right after birth can reduce brain bleeding. The goal is to see if this early support helps stabilize their condition better than the usual method.

Eligible Conditions
  • Intraventricular Hemorrhage

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at nicu admission
This trial's timeline: 3 weeks for screening, Varies for treatment, and at nicu admission for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Intraventricular Hemorrhage on Head Ultrasound or death before 7 days of age
Secondary study objectives
5 minute Apgar Score <5
Death
Lowest hematocrit in first 24 hours
+3 more
Other study objectives
Admission hypothermia <36.5°C
Apgar scores
Bronchopulmonary Dysplasia (BPD)
+27 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: VentFirst 120 Seconds Cord ClampingExperimental Treatment1 Intervention
Assisted ventilation (face mask continuous positive airway pressure, CPAP, or positive pressure ventilation, PPV) is provided prior to cord clamping at 120 seconds.
Group II: Standard 30-60 Seconds Cord ClampingActive Control1 Intervention
Standard treatment for extremely preterm infants which is delayed cord clamping 30-60 seconds after birth, and assisted ventilation after cord clamping.

Find a Location

Who is running the clinical trial?

Brigham and Women's HospitalOTHER
1,670 Previous Clinical Trials
11,877,696 Total Patients Enrolled
Indiana UniversityOTHER
1,045 Previous Clinical Trials
1,316,314 Total Patients Enrolled
University of California, DavisOTHER
946 Previous Clinical Trials
4,755,560 Total Patients Enrolled
St. Louis UniversityOTHER
194 Previous Clinical Trials
40,453 Total Patients Enrolled
University of Colorado, DenverOTHER
1,810 Previous Clinical Trials
2,919,530 Total Patients Enrolled
Oregon Health and Science UniversityOTHER
1,008 Previous Clinical Trials
7,413,619 Total Patients Enrolled
University of AlbertaOTHER
942 Previous Clinical Trials
433,839 Total Patients Enrolled
University of VirginiaLead Sponsor
785 Previous Clinical Trials
1,315,876 Total Patients Enrolled
Columbia UniversityOTHER
1,498 Previous Clinical Trials
2,766,555 Total Patients Enrolled
Mount Sinai Hospital, CanadaOTHER
204 Previous Clinical Trials
68,627 Total Patients Enrolled

Media Library

VentFirst (Assisted Ventilation) Clinical Trial Eligibility Overview. Trial Name: NCT02742454 — N/A
Intraventricular Hemorrhage Research Study Groups: Standard 30-60 Seconds Cord Clamping, VentFirst 120 Seconds Cord Clamping
Intraventricular Hemorrhage Clinical Trial 2023: VentFirst Highlights & Side Effects. Trial Name: NCT02742454 — N/A
VentFirst (Assisted Ventilation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02742454 — N/A
~60 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top